treatment for debilitating brain ailments that affects millions. the fda has approved biogen pause controversial therapy for alzheimer's disease. the drug works by removing am a lloyd, a protein that clogs the brain of alzheimer's patients. radix point to the drugs mixed record in clinical trials. there is a new sign the coronavirus pandemic is easing. global infections are fallen dramatically, with united states reporting the lowest number of daily covid 19 cases into march of 2020 worldwide infections for the week ended were also the least in almost three months. the u.s. supreme court ruled today that people who entered the u.s. illegally cannot seek permanent residency just because they are now covered by a program that gives them temporary legal status. the justices unanimously ruled against and el salvador in couple who received the status

after el salvador suffered a series of earthquakes in 2001. ruling could affect thousands of people covered by the program which attacks immigrants whose home countries are in crisis. u.s. secretary of state antony blinken is promising to expedite immigration visas for afghans who work closely with u.s. forces. testifying before the house foreign affairs committee today, secretary blinken said the u.s. is looking at what he called every option to help the afghan employees, as the pentagon pushes ahead with president biden's order to remove the troops by september 11 at the latest. texas republican congressman michael mccaul warned they would be targeted by the taliban once remaining american troops depart. global news 24 hours a day, on-air, and on bloomberg quicktake, powered by more than 2700 journalists and analysts in over 120 countries. i'm mark crumpton. this is bloomberg.

♪ matt: it is 1:00 in new york, 7:00 in berlin, 1:00 a.m. in hong kong. i'm matt miller. welcome to bloomberg markets. here are some of this top stories we are following from around the world. biogen's alzheimer's drug approved by the fda in a landmark decision that could dramatically change treatment of the debilitating brain condition. and we will speak with bob sloan of s3 partners about the recent mania in stocks which continues today. what his research is showing on the biggest shorts in the market. later on, we will speak with the founder and ceo of latch, the maker of smart building operating systems to discuss his company going public with a spac.

we see the s&p 500 down just about a quarter of 1%. the dow jones is falling a little bit more sharply as well. the 10-year yield under 1.57 right now. it has been a little bit lower throughout the day. gold might now rising, four dollars a troy ounce. bitcoin is currently under $36,000. let's dig deeper into this biogen story. it's tokyo-based partner eisai receiving approval for the controversial all cymer's disease therapy -- alzheimer's disease therapy is up right now. these are the adr's of eisai limited. biogen shares themselves are still halted, even though the news came out about three hours ago. they just had a press conference

that finished only 15 minutes ago. for more on what is going on with the drug, the approval, let's bring in senior editor jodi schneider. tell us about the treatment. this is what people are most interested in because alzheimer's affects so many surely, someone knows someone who has been affected by this horrible disease. what can this new drug do to help? >> 6 million americans are afflicted with alzheimer's. treatments in the past have only dealt with the symptoms, they have not dealt with some of the underlying causes here. that is what is such a landmark decision by the fda today, to approve this. they did it under an accelerated process. they are going to need further tests. we can talk about the controversies surrounding some of the testing, but it is landmark.

it is an antibody therapy that would be available to alzheimer's patients. obviously, important to biogen. a $5 billion potentially annual market. eisai, the japanese partner based in tokyo, will partner with biogen in manufacturing this therapy. matt: peter stein, the fda director of the office of new drugs says that patients are willing to trade some uncertainty for the possibility of results. all cymer's is a debilitating disease. it is awful to watch. a lot of people would trade anything for even a small possibility to eradicate it. trials, though, are still ongoing. >> in decades, research and development, a lot of sales

efforts in this kind of therapy by biogen and other companies, it has been a long road to this fda approval. frankly, we have not seen the fda approve anything in alzheimer's since 2003, so this is huge. but there is controversy because this therapy, while it did well in one trial, did not do well in another. skeptics say that trial where it did well could have been a fluke. proponents of the drug are saying that it did well in that therapy

in that trial because patients received more of it. so it shows that it worked well, but more trials will be needed partly because of this accelerated approval process demands it. matt: either way, it will be pretty expensive. the company saying it will cost $56,000 a year to get treatment with this drug, aducanumab, the official name. the marketing name will be aduhelm. in terms of the shares, biogen is one of the few companies that is now lower than at the start of the pandemic. it really has not moved much in terms of a one-year view, although there has been a ton of volatility. right now we are seeing a huge jump in eisai adr's, 55% in one day. biogen shares are still halted, will be resumed in about 23 minutes, but this is a moonshot bet on this treatment. >> that is a good way to put it. we have seen a ton of volatility in biogen's stock, partly because of this drug and trial. it will be expensive when this comes out.

we will see some people get it at a lower cost because it is a new trial, but as you say, it is a bet on people wanting something. this mind-wasting disease is horrible. as we have an aging population, there is a concern we will go from 6 million americans afflicted to many more. this is something that not only the scientific community but financial community, people that have aging parents or grandparents, are very interested in. these further trials will be further watched. the marketing of this drug will be closely watched. when those biogen shares start trading again, we will be watching them closely. matt: thank you very much for that, jodi schneider speaking to us about biogen and the new alzheimer's drug. something else that caught my eye, jeff bezos announced today that he will go to space next month when his company, blue

origin, launches its first passenger carrying mission. the plans to travel alongside his brother, mark, as well as someone else. there will be an auction, so you can maybe take part in go up with them and reach what we define as space. they are not going to the moon or anything, and they will only be up there for about 11 minutes. but jeff bezos, the world's richest man, $186 billion -- i think he may have more now -- will launch into space next month, two weeks after stepping down as chief executive of amazon. that will be a pretty cool trip. coming up, taking a look at the meme stocks that have been trading higher today. what is being shorted in the market right now with s3 founder bob sloan.

he's data has been invaluable to the market. we will talk to him live. this is bloomberg. ♪

matt: this is bloomberg markets. i'm matt miller. shares of amc are up again today . more than 20% after the incredible arrived last week. for more on that stock and the other meme stocks, really all a play on the shorts in this market, let's bring in bob sloan, founder of s3 partners. his data on shorting has been invaluable to market players over the past couple years. thanks for joining us.

let's talk about the revitalized jump in these meme stocks that we saw. it was really amazing to watch last week. was what we saw in amc a so-called gamma squeeze? bob: there is so much flow, derivatives happening right now. dealers, people who sell and write these options have to hedge their positions. that has caused some of the price moves, no question. matt: is amc still among the stocks that are incredibly highly shorted that you track at s3 partners? bob: if you look at our squeeze risk score it is still 100 out of 100. if you look at the size of the position, $3.6 billion. total year-to-date lost is $3.9 billion.

last week alone, shorts in amc lost $2 billion in one week. matt: unbelievable. you and i have talked about how short investors can get stocks -- sometimes over 100% --which means borrowers are relenting -- re-lending to fund the short. i see on twitter naked shorting is trending. is that still happening, is that still prevalent in this market? bob: first of all, if someone is doing naked shorting in a large-scale, scalable systematic strategy -- official should come

in and take that person in. it is against the law and should not be done. that is where we come out on it. the rules and regulations are very clear about what should happen to players that do bad. matt: on the other hand, i guess it is probably legal. if you borrow the stock from somebody and sell it to me, i can turn around and lend it to somebody else who sells it short again. is that how we get companies that are 130% shorted? bob: in your example, what has happened, you have increased the flow to the companies. you have two long position for every short sale. that is what confuses people.

there's a lot of confusion in the marketplace about what is an actual short sale. for example, a long agency sale is marked as a short sale but it is not. any investor that is long a stock, sells it, and executing broker does not have the stock in its inventory, and then sells that on to the marketplace, that is considered a short sell. there's a lot of confusion about how things are marked. that is one of the reasons we have created on bloomberg an ib chat room. there is so much confusion with the gamma hedging going on, mismarking of positions, all of this talk about naked shorting. a lot of institutional investors, hedge funds, individuals that we service on twitter, we thought we would bring the same ama to the bloomberg universe. ib s3.

we will be answering all of your questions because there are questions in the marketplace and we want to provide that service. matt: one of the most frequent questions you are asked is which stocks are ripe for a gamma squeeze. i know you have done a ton of research, you came out with that white paper showing the most squeezable stocks. has the list stayed roughly the same over the past week? bob: it is somewhat the same. nikola, some of the spac stocks definitely have high interest. amc and jeannie are still at 100. that is one of the reasons on the bloomberg terminal we will be making access to our squeeze risk score so that everyone in the marketplace, when the exchange number is released, you can see our squeeze risk score.

these things are like rogue waves. you don't see them coming until they hit you. when they hit you, they stabilize everything. one of the things that is interesting right now, you see nonstandard players do standard things. all of these things are happening, and it is telling you that even though the dogma is the company has to issue every last share it has to pay off its debt, given what is happening in the marketplace, these things can probably go on and on if nontraditional players take the place of traditional players. there is really no end in sight, how high these stocks can go. matt: always great to get some time with you, i appreciate it. i always look at the s3 blacklight score as well when

i'm looking at a stock. i know that people can ib you. ib+s3, to get into the chat with s3 partners. really interesting stuff, and it stays incredible he timely. thanks for joining us. we are getting another breaking story crossing the bloomberg terminal, one that has also been ongoing for the past couple of weeks. all of a sudden, out of nowhere, the fed started posting these massive numbers for its reverse repo facility usage. they were flatlining for months and months, and then all of a sudden, you had 40, 50 banks coming to the facility, stopping in $450 billion overnight. we now have a new record, $486 billion that banks have put at the fed's reverse repo facility. the usage is just off the

charts. not literally off the charts because our own producer has put together a chart to visualize this. you can see what i mean. this goes back to 2016, when you had a lot of these spikes. with the exception of the beginning of the pandemic, it's been very calm for the past four years, and all of a sudden we are looking at all-time records in the fed's reverse repo facility. that is something to keep in mind. still ahead, the u.s. reaches a major milestone in the fight against the pandemic. we will discuss with dr. adajya with the johns hopkins security health center. this is bloomberg. ♪

matt: this is bloomberg markets. i'm matt miller. the u.s. has passed a major

milestone against the pandemic over the weekend. according to the cdc, 300 million vaccine doses have so far been administered across the country. for more, we welcome amesh adalja, senior scholar of the bloomberg school of public health. doctor, thanks for joining us. we are always happy to celebrate the positive milestones, but i know the medical community is still worried about the number of people that have not been vaccinated in the u.s. it looks like the vaccination rate is slowing down a little bit. what are your concerns? dr. adalja: that we are hitting a wall. that the people who wanted to be vaccinated have gotten vaccinated, and that it will take additional effort to get doses in people's arms. that will leave people vulnerable. i'm in the hospital now and the people that we are seeing getting covid are on vaccinated

-- not vaccinated. we will still see cases, we will still see disruption. in general, we have tamed the virus and it simply to crush a hospital because so many have been vaccinated, but if we want covid to not be a major problem, the more people that are vaccinated, the better it will be. matt: that is great news in the u.s. we still have these serious emergencies at hospitals outside of the u.s. in terms of americans, it seems like it would be so easy to get out and get a vaccination, from what i read, from the people i talked to back home. what are the reason people tell you when they come into the hospital and have not gotten a vaccination yet? dr. adalja: it is varied. each is different, some is procrastination. that is where making it convenient helps. some are completely against the vaccine. they do not know much about it

or they think there is a conspiracy, or they are waiting for full fda approval. you try to nudge them the best you can but they are difficult. i think we have done a good job of getting the vaccine convenient to get. you can get it on the subway, even as strip ours, on the beach, anywhere you want.it is very easy to get a vaccine now. we have less procrastinators now, now a lot more like a door-to-door salesman ship. just trying to nudge them and show them this is a way back to normalcy, a way that they can improve their own personal life and free themselves of the fear of covid-19, spreading it to others or getting it themselves. matt: what is the threat from the vaccinated public from the unvaccinated? is there a concern that mutations will eventually overcome the vaccinations we have gotten? dr. adalja: for a fully vaccinated individual with a normal immune system, the

unvaccinated don't really pose a risk. the risk is really in the unvaccinated. there will always be new variants generated but our vaccines are pretty robust against the variants, the south african variant, the one discovered in india. all of those seem to be taken care of by the vaccine. but the more transmission you see the more variants you'll get, and the more difficult it will be to maintain the virus. but if you are fully vaccinated, the message is the pandemic is largely over for you. i think that is important. matt: thank you for your time. appreciate when you are doing for us. johns hopkins center for health security. of course, mike bloomberg is a contributor. this is bloomberg. ♪

♪ ♪ look, if your wireless carrier was a guy you'd leave him tomorrow. not very flexible. not great at saving. you deserve better... xfinity mobile. now they have unlimited for just $30 a month... $30. and they're number one in customer satisfaction. his number... delete it. i'm deleting it. so, break free from the big three. xfinity internet customers, switch to xfinity mobile and get unlimited with 5g included for $30 on the nations fastest, most reliable network.

amanda: welcome to bloomberg markets. i'm amanda lang. matt: i'm matt miller. we will both our bloomberg and bnn bloomberg audiences. here are the top stories we are following from around the world. biogen hat it's all cymer's drug approved by the fda in a landmark decision that could dramatically change treatment of the debilitating brain condition , and as a side effect, make owners of the stock very wealthy. we are looking for the open any second and live updates from apple's biggest event of the year as the world wide developers conference kicks off with software updates for the iphone and ipad. we will speak to the founder and ceo of latch, the maker of smart building operating systems, to discuss his company going public via spac.

it looks like the bids are opened and it is up 55%. amanda: unsurprising in some ways. we have been waiting for biogen to start treating. 15% move. in the market that is pretty quiet, but this is important news. a general feeling that this may force a re-think analyst that have been pretty neutral on biogen so far. important development for this company and for the alzheimer's space. broad look at the markets, you see a relatively flat day. the s&p 500 and nasdaq both pretty flat on the day. internals are mixed. it should be noted others in the biotech/pharma space are higher. eli lilly up 10%, so we are seeing a halo effect from biogen today. this is the kind of news that a company like this waits for. what a big day for that stock.

matt: we definitely see a lot of moves higher with this news. we had a fantastic full-screen earlier showing a bunch of biotech and pharma stocks that are up. let's get to dave wilson, who has our stock of the hour. no surprise, it is biv. biogen shares are open again after the fda approved its controversial drug against alzheimer's. maybe the drug is not as controversial as the testing regimen or the trials. of course, it will cost $56,000 a year. dave: that is certainly an eye-opening price tag, no question. this is a drug that biogen has had the rights to since 2007. it is really in the last couple of years that you have had this back and forth. it has been 18 years since you

had an alzheimer's drug approved, here in the u.s. the whole idea is that this treatment removes a protein from alzheimer's patient's brains, and that has been found to help them -- not in every study -- but in some studies. we should note, eisai, the japanese company developed this drug alongside biogen. it has been a back-and-forth for the last couple of years. the intraday chart tells you part of the story, but go back to 2019. this was a drug at one point that biogen abandoned and then redirected -- resurrected. they went to an advisable panel recommendation but they did not get it, even though they liked what they saw. now you have this approval, certainly unexpected in some quarters, given the less than conclusive data to come out of studies.

only one out of two trials was really successful on this drug. a lot to work through but the regulators did it. they erred on the side of allowing people to take it, biogen's getting the right to sell it for $56,000 a year. amanda: i think matt is perfectly correct to call it a controversial drug. it is controversial because of the data, the risk associated. we know the fda has backtracked in a way that is unusual in its history. what do you think happens to biogen, knowing there could be some real roadblocks had in terms of patient outcomes? dave: no doubt it will take time for the drug to be rolled out. that said, if you look at what analysts are anticipating in terms of revenues for biogen, before this approval, it is clear the company needed something to kickstart its growth.

you can see that in terms of projections. analysts looking all the way out to 2023. you can see earnings were there but revenues were below a peak going back to 2019. there you see the numbers. it really shows you that this drug may have a real effect on biogen's business going forward. matt: i am sure people will be clamoring for it regardless of the high price tag. hopefully, a lot of people will get a deal on that, as it is a drug and trail -- in trial, and hopefully insurance can cover it as well. most everybody, fingers crossed, hopes that it does good for those afflicted with all cymer's. -- alzheimer's. in an interview, treasury

secretary janet yellen says president biden should push forward with his $4 trillion spending plan, even if they trigger inflation. that persists into next year as well as higher interest rates. a lot to unpack, but she said, "if we end up with a slightly higher interest rate environment, it would be a plus from society's point of view and the fed's point of view as well. certainly, bankers would be happy with higher rates. amanda, they have fatter net interest margins but i wonder about the rate of inflation and its affect on the graying populations of the world, especially those of sabers living on a fixed income. amanda: in some ways with the treasury secretary is saying is obvious. in a normal market, rates would be higher. this is definitely abnormal.

the war that comes to my mind is hubris. this is a fed that believes it can hold inflation exactly where it wants it, and that has not been the history of inflation. but when it surprises you, it surprises you in a bad way. i hope they can manage this inflationary pressure. she things they can and they are willing to take the risk. matt: first of all, hubris is a great sat english word. my teacher used to tell us that all the time. secondly, bob dudley, who did once run the new york fed, is saying it is dangerous. because what the fed is doing is pushing the u.s. economy to overheat, and then we will have to raise rates faster than it normally would if it pushes up unemployment just a half a percent. that is likely to bring on a full-blown recession. amanda: we want to get now to first word news with mark crumpton.

mark: treasury secretary yellen's weekend deal with g7 counterparts on a framework for global minimum corporate tax has made for a tougher sales job in president biden's proposed changes to u.s. tax law the g7 committed to a minimum tax rate of at least 15%. that leaves a potential gap with the 21% rate that mr. biden has pitched to congress for u.s. companies profit logged abroad. congress gets back to work today and back into infrastructure talks with president biden. the president has another round of discussions today with lead gop negotiator senator shelley moore capito. over the weekend, gina raimondo said there is no hardwired deadline for an agreement. time is running short for talks this week. the president leaves on wednesday to attend the g7 summit in the u.k. airlines from britain and

the united states are issuing a plea to resume joint travel between the countries. airlines are lobbying to be included on the u.k.'s green list of nations from which passengers can skip quarantine requirements. it currently has amber status, meaning arrivals must self-isolate, which is hurting demand for leisure trips. the latest push comes days before the president is set to attend the g7 summit in england. greece said today that turkey is a safe country for the majority of asylum-seekers apart part in its shores for greece. they say the designation applies for those from syria, pakistan, bangladesh, and amalia. the price -- despite pressure from the eu, ankara has shown little interest in taking back migrants who reached greece from its territory in 2016. turkey and the eu signed an agreement that was meant to stem illegal immigration into the 27-nation bloc.

global news 24 hours a day, on-air, and on bloomberg quicktake, powered by more than 2700 journalists and analysts in over 120 countries. i'm mark crumpton. this is bloomberg.

>> the g7 has taken significant steps this weekend to end the existing harmful dynamics, making commitments today that provide tremendous momentum toward achieving a robust global minimum tax at a rate of at least 15%.

matt: this is bloomberg markets. i'm matt miller. with amanda lang. i want to quickly point out, biogen's stock has been halted for volatility. it was halted for the past three hours because the fda approved its alzheimer's drug, and then shot up 60% the minute it was on halted about 10 minutes ago. it is back to being halted. we will let you know what is going on with biib. we just listen to janet yellen talking about the corporate tax deal reached with the g7 over the weekend. . there are so many caveats here. it is only the g7. everyone now has to come back to their respective governments and get an agreement -- good luck with this congress -- and then they have to get it approved by the g20 and then broader if they want it to work. a lot of the great tax havens in the world are not the biggest governments around. amanda: that is all true,

however, what you would say if you were a proponent of any kind of harmonization on the global tax side is that it is a slow-moving process and this is a big step forward. that the u.s. is leading it is important. the big hurdle will be at home for america. it may be time to change your thinking, if you are the taiwan or ireland's of the world and figure out what your future looks like if you don't have a tax advantage you have had. i think that is arguably a healthy thing. matt: it is an interesting issue into which we will dig deeper. i often think competition is important. i know it may not prove out the best solution, in terms of a corporate tax. if you are a fan of charging corporate tax on corporations, which are already taxed at the individual owner level --

amanda: totally different subject. matt: it is, but it is related. it may not prove to be the best solution in this case. let's go to apple. apple opened its annual wwdc, worldwide developers conference, and they are taking aim at zoom, announcing they will make facetime available on the web for android and windows. zoom paring some of its gains on the news. joining us now from san francisco is emily chang. it is fascinating, we just got done talking about last week, a column talking about zoom becoming a verb

than anything else, i typically facetime people. they could be knocking this pandemic darling off of its pedestal. emily: absolutely. there are multiple use cases. i don't think zoom will be knocked off its pedestal by when apple is doing, but they can cut into some of the features that zoom has popularized over the last year. lots of new updates so far in the first 45 minutes of wwdc, apple's annual conference geared toward developers. in addition to the new futures you mentioned, they have something called a share play, playing up the idea that would allow users to play videos from disney plus, hbo max, and watch them at the same time as friends are, and then use theapp at the same time. you and your friends could be watching something on disney plus, you could order food at

the same time while watching with your friends. we have seen updates to the searchlight feature, minor upgrades to the iphone and ipad operating system. waiting for potential updates to mac, apple tv, software tracking. pretty standard wwdc unveiling so far, except except for tim cook kicking off the show today they had a range of developers kicking off the show, which was one of my favorite openings over the past few years. developers imagining their vision to the coolest opening to a wwdc. for example, tim cook stepping out on stage from a delorean with an iphone. he did not do that, but apple is trying to convince developers that apple is the best platform to build software for on the backdrop of this epic trial that

recently wrapped. amanda: are we expecting something fresh on apple epic? any decision coming down? emily: the trial wrapped a couple of weeks ago, and it could be months before we get a decision from the judge. she says she will be taking her time. she referenced prior decisions that took up to four months. we are not expecting anything in the near term but she has a number of cases piled up after this one. i don't think it will be a year, for example, but we are awaiting that decision. it is a huge decision based on the idea that apple and its app store policies are anticompetitive, that parts of the way that it operates is monopolistic. this is what epic games has argued. this is a huge moneymaker for apple, and there have been a number of developers like

spotify, for example, that have pushed back. here, apple is trying to double down and making the cell to developers, apple and its ecosystem are the best place to develop. amanda: thanks so much. we appreciate it. that is emily chang. we do want to talk about biogen, which had been halted this morning after its approval of its alzheimer's drug by the fda. it opened sharply higher, more than 50%, and then halted. open again, up 42%. we will see how this bubbles up, but some important news from the fda. we are back after this. ♪

amanda: welcome back to bloomberg markets. i'm amanda lang.

alongside matt miller. abby watch workers returned to offices, commercial real estate gradually reopening, some interesting trends are reemerging. at the center of all of the trends when it comes to technology and real estate is a company called latch, which debuted on the nasdaq today. with us now is the cofounder and ceo, luke schoenfelder. luke: thank you for having me, it is an exciting day. amanda: you have been growing fast in recent years. what changes now with this access to capital, what changes post ipo? luke: we have always had a huge vision. this gives us the ability to grow at the rate that we've been growing in multifamily, adapt to the changes we are seeing in that market, the growth of e-commerce has change the way that buildings need to be operated in, expectations that people have.

it also allows us to expand into new geographies, verticals. one that we announce a couple of weeks ago is our expansion into the commercial market space, using our operating system. as the world goes back to work, we will see a more flexible -- ways that people work in the future.ey will work at one offie tuesday and thursdays, a suburban location other days. having centralized management with your folks will be critical. we are really excited to use this moment to expand. matt: it seems more important than ever, luke. what does the live trading of shares now enable you to do? is this about incentivizing your employees? can you use stocks as currency to make acquisitions? what do you envision doing with this? luke: all of the above.

one thing we are excited about is continuing to serve our customer base. our customer base is fairly conservative. understanding we are a public company that will be here for the long haul, it really means something in our particular industry and our customer sete. we are interested partner, we work with many of the largest real estate owners in the world already, but this gives us the confidence that we will be here forever now. that opens up a new set of opportunities. we announced we are rolling out rockefeller center, brookfield place at launch. those are iconic assets that have been around for a long time. we get to do that because of the trust our customers have in us but also the faith they have in this moment, that we will be here. that is exciting. amanda: quickly, tishman is one of your backers now. does partnering with them limit

you from other partners? luke: we have had a number of significant customers over the years. it is great. this technology has been relatively slowly adopted in the industry. folks are excited to have the resources to be that r&d department for the buildings of the future. no real estate company has enough resources on their own to do it, so they turn to latch. matt: thanks for giving us your time, luke schoenfelder, latch ceo and cofounder. they are now trading publicly on the nasdaq. four amanda laying, i'm matt miller. this is bloomberg. ♪

look...if your wireless carrier was a guy, you'd leave him tomorrow. not very flexible. not great at saving. you deserve better - xfinity mobile. now, they have unlimited for just $30 a month. $30 dollars. and they're number 1 in customer satisfaction. his number? delete it. deleting it. so break free from the big three. xfinity internet customers, take the savings challenge at xfinitymobile.com/mysavings or visit an xfinity store to learn how our switch squad makes it easy to switch and save hundreds.

mark: i am mark crumpton bloomberg's first word news. the fda has made a landmark decision that could dramatically

change treatment for all cymer's disease. the fda has approved a therapy that works by removing a harmful protein that clouds the brains of alzheimer's patients. other therapies only treat dementia symptoms. this is the first fda approved treatment for all cymer's in nearly 20 years, but top scientists say it has mixed results in clinical trials. new york schools will no longer require children to wear masks outside. governor cuomo said today that any outside mask mandates will be left up to local school districts. he said that policy was approved by the cdc. the governor says lifting the mandate allows new york to align its camp and school guidance. italy aims to have 80% of its population vaccinated by september. the country's covid's told lawmakers today, in order to reach that target,